Skip to contentHome page Seeking Alpha - Power to InvestorsDec. 29, 2025 6:47 PM ETAngioDynamics, Inc. (ANGO) StockPEN, EDAPStephen Simpson20.62K FollowersCommentsAngioDynamics looks undervalued, with Med Tech segment growth in thrombus management, atherectomy, and NanoKnife driving the investment thesis.Consistent execution on revenue growth and margin improvement, especially in Med Tech, is critical for rerating; legacy Med Device business remains a headwind to sentiment.Recent clinical data for AlphaVac and NanoKnife support further adoption, while Auryon continues steady share gains in a competitive atherectomy market.Even a 2x forward revenue multiple suggests a fair value above $16, making ANGO an overlooked name if growth drivers remain intact.ChrisChrisW/iStock via Getty ImagesSlow progress is still progress, and although AngioDynamics (ANGO) arguably still does not get its due in the market, the company continues to execute at an improved level. Solid growth in the faster-growing Medical Tech segment remains the key driver, as theThis article was written byStephen Simpson20.62K FollowersStephen Simpson is a freelance financial writer and investor.Spent close to 15 years on the Street (sell-side, buy-side, equities, bonds).Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.